Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

In the wake of the 2024 U.S. elections, stakeholders in the life sciences and health care industry are intensely focused on the policy ...

A tide change is rippling across healthcare. As industry leaders converged on San Francisco for the 2025 JP Morgan Healthcare conference, they echoed optimism about a renewed stability in healthcare, ...

Another year at the J.P. Morgan Healthcare Conference is in the books. | While major payers skipped out on this year’s event, ...

UNC Health and Duke Health formed a joint venture to build a 500-bed, free-standing children's hospital in the Piedmont, ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

A major conference that took place earlier this month is set to return to San Francisco next year, according to SF Mayor Daniel Lurie’s office. The J.P. Morgan ...

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...